<DOC>
	<DOCNO>NCT01300013</DOCNO>
	<brief_summary>The primary objective study evaluate effect 48 hour intravenous ( IV ) omecamtiv mecarbil compare placebo dyspnea subject leave ventricular systolic dysfunction hospitalize acute heart failure . This multicenter , randomize , double-blind , placebo-controlled study 3 dose cohort enrol sequentially order ascend dose strength omecamtiv mecarbil . In cohort , subject randomize 1:1 omecamtiv mecarbil placebo .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy IV Infusion Treatment With Omecamtiv Mecarbil Subjects With Left Ventricular Systolic Dysfunction Hospitalized Acute Heart Failure ( ATOMIC-AHF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Male female 18 85 year Hospitalized worsen heart failure , within 24 hour initiate IV loop diuretic Dyspnea due heart failure , rest minimal exertion History leave ventricular ejection fraction ( LVEF ) â‰¤ 40 % Elevated brain natriuretic peptide ( BNP ) Nterminal fragment BNP ( NTproBNP ) Receiving IV vasopressor ( exclude low dopamine ) , inotropic mechanical support Acute coronary syndrome ( ACS ) Within 30 day prior enrollment : cardiac resynchronization therapy ( CRT ) implantable cardioverter defibrillator ( ICD ) implantation , ACS , coronary revascularization , transient ischemic attack ( TIA ) stroke , sustain ventricular arrhythmia , major surgery Severe valvular stenosis , hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis , clinically significant congenital heart disease Estimated glomerular filtration rate ( eGFR ) &lt; 20 mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Intravenous</keyword>
	<keyword>IV</keyword>
	<keyword>Left Ventricular Systolic Dysfunction</keyword>
	<keyword>Hospitalized</keyword>
	<keyword>Acute heart failure</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Left ventricular ejection fraction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>hospitalization</keyword>
	<keyword>In-patient</keyword>
	<keyword>Omecamtiv mecarbil</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
</DOC>